Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dell Technologies Inc (DELL) vs Cassava Sciences Inc (FLNA) Price & Performance

Dell Technologies IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Dell Technologies Inc vs Cassava Sciences Inc — how do they compare? Dell Technologies Inc trades at $584.66 (market cap $365.31B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Dell Technologies Inc is far larger — about 9271.8× Cassava Sciences Inc's market cap, and Dell Technologies Inc pays a 0.44% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dell Technologies Inc for 57 Days and Cassava Sciences Inc for 37 Days on average.

DELLFLNA
Market Cap
$365.31B$39.40M
Volume
5,121,365759,018
Sector
TechnologyHealth
52-Week High
$588.67$4.64
52-Week Low
$111.10$0.68
Typical Hold Time
57 Days37 Days
Enterprise Value
$388.20B-$43.28M
Dividend Yield
0.44%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dell Technologies Inc

Dell Technologies (DELL) trades at $575.33, down 0.63% on the day, but maintains a bullish technical trend with strong support near $566. The stock is buoyed by robust AI server demand, with Q2 2026 EPS beating estimates by 43% and fiscal 2027 revenue guidance raised to approximately $192 billion. Recent news highlights a 20% dividend increase and a $74 billion AI server backlog, fueling investor optimism.

Outlook remains positive given explosive AI-driven growth, but risks include execution on massive orders and competitive pressures. Analysts are largely bullish with a $566.35 consensus target, though the current price slightly exceeds it. Shareholders should monitor margin sustainability and debt levels amid rapid expansion.

Cassava Sciences Inc

FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.

The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DELL
73% Buy27% Sell
Avg holding period · 57 Days
FLNA
47% Buy53% Sell
Avg holding period · 37 Days

Top news

Latest headlines on both assets

About Dell Technologies Inc

VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses

Read more on DELL →

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA →